neointimal hyperplasia after wire-injury of the carotid artery in hyperlipidemic mice. 20 Accordingly, increased levels of JAM-A transcripts and protein have been demonstrated in human plaque biopsies and in plaque-prone aortas of mice. 21 The expression of JAM-A on inflamed and early atherosclerotic endothelium has been implicated in the recruitment of mononuclear cells through an inhibition with soluble JAM-A, suggesting a functional involvement in atherogenesis. 5 Despite being strategically positioned at junctional entry ports of arterial endothelium, less is known about the cell-specific contributions and net effect of JAM-A in directing mononuclear cell migration during atherogenic recruitment and lesion formation. To dissect the functions of JAM-A in atherosclerosis, we used apolipoprotein E-deficient (Apoe -/-) mice with a somatic or endothelial cell-specific deficiency in JAM-A and bone marrow (BM) chimeras with JAM-A-deficient leukocytes. Our data show that endothelial JAM-A promotes lesion formation by integrating effects of hyperlipidemia and disturbed flow, which result in its upregulation, redistribution, and subsequent function in promoting mononuclear cell influx into the artery wall, while limiting reverse transmigration. In contrast, leukocytic JAM-A is required for monocyte de-adhesion and complete transmigration, thereby preventing vascular damage and protecting against atherosclerosis.
Methods

Mouse Models of JAM-A-Deficiency and Plaque Formation
Somatic JAM-A -/-Apoe -/were backcrossed for >10 generations into a C57Bl/6 background. 20 Congenic Apoe -/mice were used as controls. Chimeric mice with a leukocytic JAM-A deficiency were obtained by reconstituting Apoe -/recipients with JAM-A -/-Apoe -/or JAM-A +/+ Apoe -/-BM. 22 A genetic reduction of endothelial JAM-A was achieved by crossing Apoe -/mice with a loxP-flanked (floxed) JAM-A gene (JAM-A fl/fl ) with VeCad-CreERT 2 Apoe -/mice to obtain VeCad-CreERT 2 JAM-A fl/fl Apoe -/mice (C57Bl/6). 23 At an age of 3 weeks, 5 daily intraperitoneal injections of the estradiol analog tamoxifen (0.04 mg/g) dissolved in miglyol 810 were administered to VeCad-CreERT 2 -positive or VeCad-CreERT 2 -negative animals to obtain eJAM-A -/-Apoe -/or eJAM-A +/+ Apoe -/mice, respectively. After 4-6 weeks, genetic depletion of JAM-A was confirmed by FACS analysis, resulting in ≈50% less endothelial JAM-A levels with no difference in leukocytic JAM-A levels compared with control mice. We chose a mouse model with an inducible endothelium-specific Crerecombinase, because constitutive expression of Cre-recombinase under the control of endothelium-specific promoters (e.g. Tie2/Tek, VE-cadherin) can lead to deletion of the floxed gene in hematopoietic cells. 24, 25 Plaque formation was induced in female littermates (aged 6-8 weeks, n=10-13) by feeding a high-fat diet (HFD, 21% fat, 0.15% cholesterol) for 12 weeks or by partial ligation of the carotid artery, resulting in altered shear stress attributable to reduced and partially retrograde blood flow. 26 In brief, Apoe -/mice (n=5) were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg), and left external and internal carotid, and occipital artery were ligated with 6-0 silk sutures, leaving only superior thyroid artery open. Animal experiments were approved by local authorities and complied with German animal protection law (LANUV NRW, Recklinghausen, Germany).
Quantification and Immunohistochemical Analysis of Atherosclerosis
Plaques and lipid depositions in aortic roots and in thoracoabdominal aortas were visualized by Elastica van Gieson or Oil-red-O staining, respectively, and quantified by computerized image analysis. 22 The relative content of macrophages and CD3 + T-cells was determined by staining with anti-Mac-2 and anti-CD3, and detection with FITCand Cy3-conjugated antibodies. Nuclei were visualized with DAPI. Necrotic core areas were quantified in DAPI-stained slices of aortic roots. Stages of atherosclerotic lesions were determined by evaluation of Elastica van Gieson-stained aortic roots. 27 
Stimulation of Endothelial Cells Under Static or Flow Conditions
Human aortic endothelial cells (HAoECs) without genetic modification, and JAM-A +/+ Apoe -/or JAM-A -/-Apoe -/-SV40-large T antigen-immortalized mouse ECs (SVECs) were grown on collagenized glass slides or Bioflux 48-well plates, respectively. HAoECs were treated with low-density lipoprotein (LDL), oxidized LDL (oxLDL; both 10 µg/ml, 16 h), TNF-α and IFN-γ (10 ng/ml and 20 ng/ml, 4 h, respectively), or oxLDL plus JAM-A.Fc (10 µg/ml, 15 min). Mouse ECs were activated for at least 4 h with TNF-α (25 ng/ ml). For culture under flow conditions, HAoECs were transferred to 0.4-µm µ-slides (ibidi, Martinsried, Germany). Cell culture was continued under static or flow conditions for 48 h, while shear stress was gradually increased to 5 or 20 dyn/cm 2 using an ibidi pump system.
In Vitro, Ex Vivo, and In Vivo Monocyte Adhesion and Transmigration Assays
CD14 + human monocytes and CD115 + mouse monocytes were freshly isolated from human blood or mouse spleens using Monocyte Isolation Kit II or the CD115 mouse MicroBead Kit and were applied on endothelial cells under shear stress (1.5 dyn/cm 2 ) in a laminar flow chamber for up to 10 min and flushed with assay medium for 30 min during time-lapse recordings. Monocytes showing complete, reverse, and incomplete transmigration were counted relative to adherent or total transmigrated monocytes. Human studies were approved by the institutional review board and informed consent was given by the subjects.
For de-adhesion assays, JAM-A +/+ and JAM-A -/-CD115 + monocytes were allowed to adhere on TNF-α-stimulated SVEC monolayers or coated intercellular adhesion molecule-1.Fc protein at 0.75 dyn/cm 2 in µ-slides 0.4 . Shear stress was gradually increased to 11.5 dyn/cm 2 and monocytes remaining adherent were counted.
Carotid arteries of Apoe -/mice were explanted, mounted, pressurized at 80 mm Hg, and incubated with FITC-coupled CD31 antibody (5 µg/ml). After stimulation of carotid arteries with TNF-α (10 ng/ ml, 3 h), Rhodamine B-stained (1 µg/ml) primary CD115 + monocytes with and without JAM-A deficiency (6×10 5 cells) were perfused in the mounted and pressurized vessel at 0.4 ml/min and visualized using 2-photon laser scanning microscopy (TPLSM).
The right carotid arteries of eJAM-A -/and eJAM-A +/+ mice were challenged with interleukin-1β (2 µg/ml) carried by a slowly degrading periarterial pluronic gel for 24 h. In addition, Alexa Fluor (AF) 568-coupled anti-CD115 antibody (5 µg/mouse) was administered intravenously. On the next day, anaesthetized mice were injected intravenously with anti-CD31 FITC-coupled antibody (35 µg/mouse total) and prepared for in vivo TPLSM by surgically exposing the common carotid artery. 28
TPLSM of the Carotid Artery In Vitro and In Vivo
Imaging was performed using a resonant scanning Leica SP5MP (in vivo) or an Olympus FV1000MP with a pulsed Ti:Sapphire Laser tuned at 800 nm and a 20×NA1.00 (Leica) or a 25×NA1.05 (Olympus) water immersion objective. 28
Fluorescent Bead Assay
HAoECs were incubated with fluorescent microbeads (≈1 µm diameter) coupled to JAM-A antibodies (clone 246) for 30 min. Nuclei were stained with HOECHST 33342. After washing, bright field and fluorescent images were recorded. Bead numbers were related to nuclei count and normalized to binding of immunoglobulin-coupled control beads.
MiR-145 Transfection of HAoECs
HAoECs grown to 80% confluence were transfected with microRNA (miR)-145-3p or miR-145-5p mimics (75 pmol/L) using Lipofectamine 2000. Quantitative (q)PCR analysis of JAM-A mRNA and miR-145 levels was performed after 24 h using established protocols. 5, 29 
Statistical Analysis
Statistical analysis was performed using Prism 6.0 (GraphPad Software). Means were compared between 2 groups by 2-tailed, unpaired, or paired Student t test, without or with Welch correction or among more than 2 groups by 1-way ANOVA with Tukey or Bonferroni post test or Kruskal-Wallis test with Dunn post test, as indicated. Differences with P<0.05 were considered as statistically significant.
For more detailed information please see the online-only Data Supplement.
Results
Deficiency in Endothelial JAM-A Protects Against Atherosclerosis
The inhibition of mononuclear cell recruitment by soluble JAM-A has implicated JAM-A in atherogenesis, 5 however, owing to its pleiotropic functions the overall and cell-specific effects of JAM-A have remained elusive. Notably, somatic JAM-A deletion did not significantly affect atherosclerotic lesion area in the thoracoabdominal aorta and the aortic root of Apoe -/mice fed a HFD for 12 weeks ( Figure 1A 
Endothelial JAM-A Deficiency Reduces Lesional Infiltration
Immunohistochemistry in the aortic root revealed that the lesional content of Mac-2 + macrophages did not differ in somatic JAM-A -/-Apoe -/mice versus JAM-A +/+ Apoe -/controls ( Figure 2A ). As compared with control chimeras, JAM-A deficiency in BM-derived cells reduced macrophage content ( Figure 2B ). Likewise, deficiency in endothelial JAM-A markedly decreased macrophage content, as compared with controls with intact JAM-A ( Figure 2C and 2D). The infiltration with CD3 + T-cells characterizing early lesion stages was unaffected by somatic deletion of JAM-A but markedly reduced in mice with JAM-A-deficient leukocytes or with an endothelial deficiency in JAM-A ( Figure 2E-2G ). As a hallmark for advanced lesions, necrotic core size was unaltered by somatic deletion of JAM-A, higher in mice with JAM-A-deficient BM-derived cells, indicative of increased macrophage turnover, and considerably reduced by endothelial deficiency in JAM-A ( Figure 2H -2J). To evaluate the rate of lesion development in these mice, we performed a phenotypic classification. 27 Whereas JAM-A -/-Apoe -/and leuJAM-A -/-Apoe -/mice developed lesions that were mainly in an advanced stage, eJAM-A -/-Apoe -/mice almost exclusively bore lesions in initial or intermediate stages, displaying an increase in early lesion stages, as compared with controls ( Figure 2K ). Whereas the preponderance of advanced lesions in chimeric mice is likely related to irradiation, a higher proportion of 
Role of Endothelial JAM-A in Arterial Leukocyte Recruitment
We used in vivo, ex vivo and in vitro adhesion and transmigration assays to mechanistically evaluate the role of endothelial and leukocytic JAM-A in arterial monocyte recruitment. Indeed, we found a lower number of wild-type CD115 + monocytes that had crossed the endothelial layer of carotid arteries in eJAM-A -/mice after treatment with interleukin-1β, as compared with eJAM-A +/+ controls, both during in vivo recording ( Figure 3A ) and in situ after sacrifice ( Figure 3B ). Accordingly, the adhesion of wild-type monocytes to JAM-A-deficient endothelial monolayers stimulated with TNF-α/IFN-γ was unaltered but their transmigration underneath JAM-A-deficient endothelial monolayers was markedly reduced, compared with JAM-A-bearing endothelial cells ( Figure 3C and 3D). The decreased transmigration of monocytes across JAM-A-deficient endothelial cells might also be explained by an increase in reverse transmigration, which was only observed when JAM-A +/+ leukocytes transmigrated across JAM-A-deficient endothelial cells ( Figure 3E ).
Leukocytic JAM-A Deficiency Impairs De-Adhesion and Endothelial Barrier Function
As compared with wild-type monocytes, JAM-A -/mouse monocytes showed a marked increase in firm adhesion to ex vivo perfused wild-type carotid arteries ( Figure 3G ) and to JAM-A +/+ endothelial cells in a recruitment assay under flow conditions in vitro ( Figure 3C ). This was accompanied by reduced transmigration of JAM-A -/monocytes ( Figure 3D ), which may be attributable to a defect in de-adhesion. 12 JAM-A -/monocytes showed a higher rate of incomplete transmigration (defined as cells that had entered endothelial junctions without exiting, thus being entrapped) across both JAM-A-expressing or JAM-A-deficient endothelial cells ( Figure 3F ), explaining the overall decrease in complete transmigration ( Figure 3D ). To confirm defective de-adhesion of JAM-A -/monocytes, we performed assays under variable flow conditions. Compared with JAM-A +/+ controls, adherent JAM-A -/monocytes were more resistant to shear stress and detachment induced by gradually increasing flow rates both on stimulated SVEC monolayers ( Figure 3H ) and the β2 integrin ligand intercellular adhesion molecule-1.Fc ( Figure 3I ). This clearly indicates that de-adhesion was impaired in JAM-A -/monocytes and that this effect was likely mediated by increased activity of β2 integrins.
Because compromised endothelial integrity is a hallmark of early atherosclerosis, 30 we investigated the permeability of the carotid artery wall of Apoe -/mice deficient in leukocytic and endothelial JAM-A fed with or without HFD for 6 
by guest on June 9, 2017 http://circ.ahajournals.org/ Downloaded from weeks. As assessed by ex vivo TPLSM, the uptake of fluorescent dextran into the arterial media was not affected by HFD or endothelial JAM-A deficiency but increased by histamine-treatment or leukocytic JAM-A-deficiency ( Figure 3J ) Altered vascular permeability in leuJAM-A -/-Apoe -/mice may reflect the damage inflicted by impaired de-adhesion or transmigration of leuJAM-A -/leukocytes and may explain increased lesion formation.
Focal Redistribution of Endothelial JAM-A in Lesion-Prone Areas
Analysis of atherosclerotic arteries and plaque tissue revealed an increase in JAM-A expression. 5, 21 We used ex vivo 2-photon laser scanning microscopy (TPLSM) in unfixed and intact carotid arteries of Apoe -/mice to label JAM-A and to determine its distribution in plaque-prone vessels as a potential mechanism underlying atherogenic leukocyte recruitment ( Figure I 
Oxidized LDL Increases Functional JAM-A Expression
To elucidate whether the focal accumulations of endothelial JAM-A in atherosclerotic lesions are caused by redistribution or increased de novo synthesis, we performed JAM-A antibody-coupled fluorescent bead assays, real-time PCR, and Western blot analysis. Similar to costimulation with TNF-α and IFN-γ, treatment with oxLDL but not with native LDL increased specific surface binding of anti-JAM-A microbeads to aortic endothelial cell monolayers ( Figure 5A and 5B). Blocking de novo protein synthesis with cycloheximide partially yet nonsignificantly reduced JAM-A surface levels, suggesting that both increased expression and redistribution contributed to the up-regulation of endothelial surface JAM-A. Treatment with oxLDL but not native LDL or TNFα, dose-dependently increased JAM-A transcript and protein expression in HAoECs, reaching a plateau at 2.5 µg/ml of oxLDL ( Figure 5C ). To link JAM-A expression to atherogenic recruitment, we performed a transmigration assay using classical CD14 + monocytes and HAoECs under shear flow conditions ( Figure 5D ). Similar to costimulation with TNF-α/ IFN-γ, treatment with oxLDL but not native LDL caused an increase in monocyte transmigration. Notably, blocking endothelial JAM-A with soluble JAM-A.Fc reduced the oxLDLinduced increase in transmigration to levels seen in untreated HAoECs, indicating that the effect of oxLDL on transmigration is mediated by JAM-A.
The Expression and Localization of JAM-A Is Governed by Shear Flow and miR145
Because the increased susceptibility to lesion formation in areas near bifurcations or branching points is related to altered flow conditions (eg, low or oscillatory flow), we tested whether such aberrant flow conditions as induced by partial ligation of the carotid artery of Apoe -/mice affects the localization of JAM-A. Indeed, costaining for JAM-A and CD31 revealed a discontinuous pattern of JAM-A and redistribution from the junctions in the common part of partially ligated carotid arteries, as seen in the bifurcation of mice with established lesions ( Figure 6A and Figure II in the online-only Data Supplement). The redistribution of JAM-A was evident both in the common part and in the bifurcation, as early as 2 weeks after ligation ( Figure 6A ). The pseudo-overlap of JAM-A with CD31 was markedly reduced in carotid arteries after 2 weeks and this reduction sustained for at least 8 weeks after partial ligation ( Figure 6B ), indicating that JAM-A is preferentially redistributed from its junctional expression pattern under conditions of disturbed flow. Conversely, the control of JAM-A might be linked to atheroprotective laminar flow conditions. Hence, we assessed JAM-A expression in HAoECs cultured under static or flow conditions, revealing an inverse correlation of JAM-A expression with laminar shear flow ( Figure 6C and 6D) . To correlate this effect with a JAM-A-dependent local predilection for atherosclerosis, Figure 6E and 6F). Recent evidence has linked the expression of miR-145 in endothelial cells under shear flow conditions to the mechanosensitive transcription factor Krüppel-like factor 2. 31, 32 Indeed, culture of HAoECs under shear flow conditions increased the expression of miR-145, as compared with static conditions ( Figure 6G) . Notably, an analysis of miR target sequences revealed that the gene of JAM-A harbors at least 2 seed sequences for miR-145-3p and miR-145-5p (see Figure III in the online-only Data Supplement). To investigate whether JAM-A expression is regulated by a miR-145-dependent mechanism, we transfected HAoECs with miR-145-3p and miR-145-5p mimics. Notably, both the miR-145-3p and miR-145-5p strands reduced the copy number of JAM-A mRNA in HAoECs ( Figure 6H ). These findings suggest that miR-145 is a flow-dependent regulator of JAM-A expression, which may protect against plaque formation by attenuating JAM-A mRNA levels under flow conditions. Taken together, endothelial JAM-A levels might serve to functionally integrate atherogenic risk factors, such as modified LDL and disturbed flow conditions.
Discussion
Here we have unraveled the cell-specific effects and mechanisms exerted by JAM-A in diet-induced atherosclerosis, and the overall and context-dependent consequence of its genetic deficiency. Previous studies have reported differential or even contradictory effects of somatic and endothelial JAM-A deficiency in various models of tissue injury and inflammation. 14, 17, 33, 34 This apparent inconsistency may be attributable to the use of heterogeneous models affecting different vascular beds. We used diet-induced atherosclerotic lesion formation and arterial inflammation in Apoe -/mice and found that endothelial JAM-A promoted lesion formation and mononuclear cell infiltration. This effect was mediated by an elevated accessibility of JAM-A (through upregulation and redistribution) and its function in guiding monocyte recruitment, which was stimulated under atherogenic conditions. The expression and luminal enrichment of JAM-A was exacerbated by disturbed flow conditions (eg, reduced shear flow), as encountered at predilection sites, whereas laminar shear flow induced miR-145 to repress JAM-A expression, in a mechanism that may contribute to limiting the susceptibility to atherosclerosis. Targeting endothelial JAM-A may thus serve as a feasible option to protect against atherogenic inflammation.
In contrast, we demonstrate that JAM-A deficiency in BM-derived leukocytes aggravates atherosclerotic lesion formation. Dendritic cells deficient in JAM-A display higher migratory capacity in lymphoid organs but not in blood vessels, 11 whereas JAM-A-deficient polymorphonuclear cells show reduced diapedesis in peritonitis and ischemia-reperfusion injury, related to impaired de-adhesion and polarized motility. 12 We found that JAM-A-deficient monocytes indeed display defects in de-adhesion and complete transendothelial migration, likely a result of persistently increased activity of β2 integrins. Consequently, monocytes become entrapped between the endothelial cell layer and the basement membrane and may thereby cause vascular damage. Our data thus indicate that the presence of leukocytic JAM-A may limit atherogenic damage by enabling physiological de-adhesion and migration of mononuclear cells. No significant alterations of atherosclerotic lesion formation were found in mice with somatic JAM-A deletion, pointing towards an intermediate phenotype between the atherogenic influence of endothelial JAM-A and the protective functions of leukocytic JAM-A. Notably, the reduction in Mac-2 + and CD3 + cell content in mice with either endothelial or leukocytic deficiency in JAM-A was not recapitulated in JAM-A -/mice, where no difference could be observed. This may be attributable to counteracting effects of JAM-A deficiency in cells other than endothelial and BM-derived cells (e.g. smooth muscle cells, pericytes, or non-BM-derived resident macrophages). The intermediate phenotype was also reflected in the classification of lesion stages. In general, irradiation for BM reconstitution appeared to accelerate the development of more advanced stage plaques, whereas the deficiency in endothelial JAM-A delayed lesion progression and clearly favored a retention in early lesion stages.
We used various assays to assess the capacity of JAM-Adeficient leukocytes or endothelial cells to support recruitment in vivo, ex vivo and in vitro and we provide novel in vitro evidence that a deficiency in endothelial JAM-A might also allow for monocytes to reappear on the monolayer by passively permitting reverse migration, contributing to the overall decrease in complete transmigration. This retentive control exerted by JAM-A complements a reverse gate-keeper function revealed for JAM-C in a study in which blocking JAM-C reduced the number of monocytes in inflammatory tissue by increasing reverse transmigration. 35 Accordingly, a hesitant or reverse transmigration behavior has been identified for neutrophils during inflammation after ischemia-reperfusion injury in vivo, which was characterized by lower expression of JAM-C at endothelial junctions, enhanced by blockade or genetic deletion of JAM-C 36 , and implicated in systemic dissemination of inflammation.
Mechanistically, the exacerbation of atherosclerotic lesion formation by endothelial JAM-A appears to be attributable to its redistribution from the intercellular junctions to the luminal surface, and to an upregulated expression under atherogenic conditions, thus increasing the availability of luminal JAM-A. Previous work has addressed the redistribution of [15] [16] [17] 34 We extend these findings by unveiling a focal upregulation and redistribution of JAM-A expression in endothelial cells of carotid arteries under atherogenic conditions of hyperlipidemia. The increased luminal JAM-A availability could mediate enhanced recruitment and higher content of macrophages and T-cells in atherosclerotic plaques of hyperlipidemic mice. In vitro experiments confirmed that oxidized LDL increased expression of JAM-A and its redistribution to the apical surface.
Our data challenge the intuitive assumption that knockingout a protein that is crucially involved in junctional barrier function would cause a nonspecific influx of leukocytes. Rather, the evidence presented in this study refutes a role of JAM-A in limiting transendothelial migration and points towards a specific role of JAM-A in leukocyte recruitment in the context of atherosclerosis. First, genetic deficiency in endothelial JAM-A decreased infiltration of plaques with macrophages and T cells and reduced luminal monocyte extravasation in carotid arteries in vivo. Second, redistribution of JAM-A induced by oxLDL facilitated the transmigration of monocytes.
The increase in expression and focal redistribution of JAM-A in response to atherogenic stimulation with oxLDL reveals a striking similarity to JAM-C, a related JAM family member, which displays increased expression and redistribution to the apical surface after oxLDL treatment. 37 Like for JAM-A, JAM-C predominantly localized to interendothelial contacts under quiescent conditions, oxLDL induced a disorganized JAM-C localization that was no longer restricted to interendothelial junctions, and JAM-C supported both adhesion and transmigration upon oxLDL stimulation. 37 The upregulation and luminal redistribution of JAM-A is enhanced by aberrant shear flow conditions (e.g. after partial ligation or at predilection sites), whereas laminar shear flow appears to exert beneficial effects on JAM-A, limiting the susceptibility to atherogenesis. Accordingly, the reduction of atherosclerotic lesion formation in the aortic arch was more prominent in regions of low shear rather than high shear (e.g. the inner curvature of the arch and branching points of the descending aorta). Of note, Krüppel-like factor 2-transduced or shear stress-stimulated human endothelial cells have been found to be enriched in miR-143/145, providing a mechanism for atheroprotective communication with neighboring SMCs via miR-145-containing microvesicles. 32 Our data confirmed that shear flow induces an increase in miR-145 expression in arterial endothelial cells, which is highly relevant and extends findings identifying JAM-A as a miR-145-target in tumor cells. 38 The overexpression of miR-145 suppressed the expression of JAM-A in endothelial cells, which was mirrored by the flow-dependent reduction in JAM-A expression. Thus, miR-145 is a regulator of JAM-A in the setting of arterial remodeling.
Notably, platelet endothelial adhesion molecule-1 (PECAM-1), another Ig family adhesion molecule expressed on platelets, leukocytes, and endothelial cell junctions, has recently been found to regulate atherosclerotic plaque formation in a cell-and site-specific manner. 39 In contrast to JAM-A, PECAM-1 on BM cells was proatherogenic irrespective of the hemodynamic environment, whereas PECAM-1, like JAM-A, reduced lesion formation in areas of disturbed flow but was atheroprotective in high shear regions by mechanisms yet to be elucidated.
In the context of arterial denudation injury, the neointimal content of macrophages was reduced in mice with a somatic JAM-A deletion. This was likely attributable to a reduced JAM-A-dependent deposition of the chemokine CCL5 by platelets on the luminal surface of injured arteries. 20 Moreover, the phenotype of regenerating endothelial cells after wire-injury may differ, benefiting from increased JAM-A expression and its function in endothelial cell migration and shear resistance. 40 Our study identifies the differential and cell type-specific contribution of JAM-A in atherosclerosis, namely a crucial involvement of endothelial JAM-A in atherogenic leukocyte recruitment in response to modified lipids and at predilection sites with disturbed flow. Increased expression and focal redistribution of JAM-A controlled by miR-145 establish a novel set of mechanisms to explain the higher susceptibility to atherosclerosis in regions with disturbed shear flow. Endothelial JAM-A may serve as a suitable marker for molecular imaging of early stages of lesion formation and may be developed as a therapeutic target to treat atherosclerosis. 
Online Methods
Mouse models of JAM-A-deficiency and plaque formation
Somatic JAM-A -/-Apoe -/were backcrossed for >10 generations into a C57Bl/6 background 1 .
Congenic Apoe -/mice were used as controls. Chimeric mice with a leukocytic JAM-A deficiency were obtained by reconstituting Apoe -/recipients with JAM-A -/-Apoe -/or control Inc., West Grove, PA). Nuclei were visualized with DAPI. Necrotic core areas were quantified in DAPI-stained slices of aortic roots. Images were recorded with a Leica DMLB fluorescence microscope and CCD camera. Stages of atherosclerotic lesions were determined by evaluation of EVG-stained aortic roots, as reported by Virmani et al. 7 .
Stimulation of endothelial cells under static or flow conditions
Human aortic endothelial cells (HAoECs) without genetic modification, and JAM-A +/+ Apoe -/or JAM-A -/-Apoe -/-SV40-large T antigen-immortalized mouse ECs were grown on collagenized glass slides or in specialized 48-well plates (IUL Instruments, Königswinter, Germany), respectively. HAoECs were treated with LDL, oxLDL (both 10 µg/ml, 16 h), TNF-α and IFN-γ (10 ng/ml and 20 ng/ml, 4 h, respectively) or oxLDL plus JAM-A.Fc (10 µg/ml, 15 min). Mouse ECs were activated for at least 4 h with TNF-α (25 ng/ml). For culture under flow conditions, HAoECs were harvested from static cultures and transferred to 0.4 µm µslides (ibidi, Martinsried, Germany). After attachment, cell culture was continued under static or flow (both 48 h) conditions, while shear stress was gradually increased to 5 or 20 dyn/cm 2 using an ibidi pump system.
In vitro, ex vivo and in vivo monocyte adhesion and transmigration assays
CD14 + human monocytes and CD115 + mouse monocytes were freshly isolated from blood from healthy volunteers or from spleens of mice with the respective genetic modification, respectively, for every experimental series using the Monocyte Isolation Kit II or the CD115 mouse MicroBead Kit (Miltenyi, Bergisch Gladbach, Germany), which employ blocking reagents for the Fc-receptor. Human monocytes (0.7×10 6 /ml) were applied on HAoECs under shear stress (1.5 dyn/cm 2 ) using a syringe pump (WPI, Berlin, Germany) in a laminar flow chamber for 5 min and flushed with assay medium for 30 min, while time-lapse images were recorded (Cell M system, Olympus, Tokyo, Japan). Mouse monocytes (2×10 6 /ml) were applied on stimulated mouse ECs under shear stress (0.8 dyn/cm 2 , BioFlux 200, IUL Instruments) for 10 min and flushed with assay medium for 30 min, while time-lapse images were recorded.
Monocytes showing complete, reverse and incomplete transmigration were counted and related to adherent or transmigrated monocytes. Human studies were approved by the institutional review board and informed consent was given by the subjects.
Carotid arteries of Apoe -/mice were explanted, mounted, pressurized at 80 mmHg and incubated with FITC-coupled CD31 antibody (5 µg/ml, BD Biosciences, San Jose, CA). After staining of monocytes with Rhodamine B (1 µg/ml, Sigma Aldrich, Carlsbad, CA) and stimulation of carotid arteries with TNF-α (10 ng/ml, 3 h, eBioscience, San Diego, CA), primary CD115 + monocytes with and without JAM-A deficiency (3 ml of 2×10 5 cells/ml) were perfused in the mounted and pressurized vessel at 0.4 ml/min, and monocytes were counted via 2-photon laser scanning microscopy (TPLSM).
The right carotid arteries of eJAM-A -/and eJAM-A +/+ mice were challenged with IL-1β (2 µg/ml, BioLegend, San Diego, CA) carried by a slowly degrading periarterial pluronic gel for 24 h. In addition, Alexa Fluor (AF) 568-coupled anti-CD115 antibody (5 µg/mouse, eBioscience, San Diego, CA) was administered intravenously. On the next day, anaesthetized mice were injected intravenously with anti-CD31 FITC coupled antibody (35 
